Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$9.94
-0.22 (-2.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $100.2M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
14.2x
↓EV/EBITDA
10.0x
↓ROE
17.9%
↑Gross Margin
72.0%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.9%
FCF CAGR
+29.3%
FCF margin
16.2%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.75B · net income $306.4M · FCF $282.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.75B | $1.75B | $1.78B | $1.63B | $1.79B |
| Net Income | $306.4M | $306.4M | $255.2M | $186.8M | $285.9M |
| EBITDA | $448.6M | $448.6M | $384.0M | $298.4M | $427.8M |
| EPS | 0.70 | 0.70 | 0.58 | 0.42 | 0.66 |
| Gross Margin | 72.0% | 72.0% | 71.8% | 68.1% | 67.3% |
| Operating Margin | 18.6% | 18.6% | 16.0% | 12.6% | 11.7% |
| Net Margin | 17.5% | 17.5% | 14.4% | 11.5% | 16.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.43 | 0.47 | 0.38 |
| Current Ratio | 0.91 | 0.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $282.1M | $282.1M | $100.2M | $-131.2M | $130.4M |
| Returns | |||||
| ROE | 17.9% | 17.9% | 15.7% | 12.8% | 20.6% |
| Valuation | |||||
| P/E | 14.20 | 14.20 | 17.84 | 26.62 | 12.53 |
| EV/EBITDA | 10.04 | 10.04 | 12.88 | 18.25 | 8.68 |
| P/B | 2.54 | 2.54 | 2.81 | 3.41 | 2.58 |
| Growth & Yield | |||||
| Revenue Growth | -1.7% | -1.7% | 9.1% | -9.1% | — |
| EPS Growth | 20.7% | 20.7% | 38.1% | -36.4% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.0%
EPS terminal req.
$0.88
Spread vs growth
12.7%
5Y implied EPS CAGR
8.8%
EPS terminal req.
$1.07
Spread vs growth
11.9%
10Y implied EPS CAGR
9.4%
EPS terminal req.
$1.72
Spread vs growth
11.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.4%
Start / end P/E
17.2x → 14.2x
EPS bridge
0.58 → 0.70
Residual
-3.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.